Genetic polymorphisms associated with therapeutic response and adverse effects to methotrexate in Taiwanese patients with rheumatoid arthritis: a real-world, hospital-based study
Real-world analysis explores genetic influences on methotrexate response and side effects in Taiwanese RA patients, indicating the potential for personalized treatment.
Key Points
This study aims to identify genetic factors affecting the therapeutic response and adverse effects of methotrexate in patients with rheumatoid arthritis.
Retrospective analysis of 1,948 RA patients receiving MTX treatment from January 2009 to January 2022.
Chi-square analysis used to compare carrier ratios of 82 selected SNPs related to MTX response.
Logistic regression employed to assess associations between genetic variants and non-response or adverse effects, adjusting for confounders.
ABCC1 rs212090 associated with better MTX efficacy (p = 0.016).
ABCC3 rs2277624 and rs4148416 linked to lower MTX response rates (p = 0.004 and p = 0.023).
SNPs in ADORA3 rs2298191 and ABCC4 rs7317112 associated with higher risk of thrombocytopenia (p = 0.045 and p = 0.049).